San Salvador, Mar 4 (Prensa Latina) Progress in clinical trials for the Cuban Soberana 02 vaccine project against the SARS-CoV-2 coronavirus, which causes Covid-19, was highlighted on Salvadoran CoLatino daily on Thursday.
The oldest printed daily in El Salvador reported the authorization of the third phase of clinical trials of this vaccine candidate, developed by the Finlay Institute, Cuba.
CoLatino highlighted that Soberana 02 is the first Covid-19 vaccine candidate to reach phase three in Latin America, and its positive results are reported by media outlets such as the BBC and The New York Times.
In this regard, political analyst Dagoberto Gutierrez commented to TVX channel 'Cuba's exploit as the single Latin American country that has developed vaccines, despite obstacles.'
In addition, several voices in the solidarity movement with Cuba and left-wing deputies usually share news on the island's progress in the fight against the pandemic on social media and public spaces.
Cuba has five vaccine projects, three of which are developed by the Finlay Institute (Soberana 01, Soberana 02 and Soberana 01-A), and two by the Center of Genetic Engineering and Biotechnology, named Abdala and Mambisa.
rly/aph/mgt/cmv
CoLatino highlighted that Soberana 02 is the first Covid-19 vaccine candidate to reach phase three in Latin America, and its positive results are reported by media outlets such as the BBC and The New York Times.
In this regard, political analyst Dagoberto Gutierrez commented to TVX channel 'Cuba's exploit as the single Latin American country that has developed vaccines, despite obstacles.'
In addition, several voices in the solidarity movement with Cuba and left-wing deputies usually share news on the island's progress in the fight against the pandemic on social media and public spaces.
Cuba has five vaccine projects, three of which are developed by the Finlay Institute (Soberana 01, Soberana 02 and Soberana 01-A), and two by the Center of Genetic Engineering and Biotechnology, named Abdala and Mambisa.
rly/aph/mgt/cmv
Temas Relacionados:
